Published Date:2024-05-09 Original Link:https://www.onenessbio.com/en/news_detail284_4.htm No 1 Date of announcement 2024/05/09 Time of announcement 17:52:36 Subject S.C. injection formulation of FB825 has been agreed by US FDA to proceed with Phase 2 clinical trial to treat moderate-to-severe atopic dermatitis. To which item it meets paragraph 10 Date of events 2024/05/09 Statement Date of occurrence of the...Read More